Renal Cancer Clinical Trial
Official title:
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer
Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative to surgery to control localized primary renal cell cancer (RCC) in medically inoperable patients. The kidney tumor has classically been considered radioresistant. Multiple retrospective series and few Phase II trial have studied the role of SBRT in localized renal tumors with favorable outcomes. Although large prospective studies are lacking, we evaluate the safety and effectiveness of SBRT for the treatment of renal cancer. Participants will be allocated to recieve either single 26Gy fraction or Multifraction 3 - 5 fraction-squeme. Assesment at regular intervals will estimate the activity and efficacy of the technique, evaluate tolerability, estimate survival, estimate distant failure rate, and renal function change after SABR. Follow-up visits occur at 1month and every 3 months in the first year after SBRT, then every 6 months in the second year and then yearly until study closure. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
| Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
| Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
| Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
| Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
| Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
| Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
| Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 |